Saturday 17 October 2026 Export PTCT’s income statement to Excel — free account

PTC Therapeutics, Inc.

PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

59.24 1.75 −2.87%

Follow PTCT

Alert me

Market cap: $5.1B
P/E: 0.0×
Fwd P/E: 110×
Dividend yield: —
F-score: 7/9
Altman Z: 1.86
Beneish M: −1.48
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 56.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	6	5	16	8	5	4	3	6	5	4	3	3

Insider Ownership 2.57%

Capital & Financial Ratios $m

Market Cap 5,090.00

Revenue 1,008.75

Net Income (38.38)

Free Cash Flow (300.25)

Net Debt 683.32

Current Ratio 3.39

Debt/Equity (17.61)

P/E ratio 0.00

Fwd P/E 110.00

P/S ratio 4.87

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (83.86%)

Next Y EPS Growth 95.69%

Next Y revenue growth (27.37%)

Next 5Y EPS Growth (19.48%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 39.70%

10-year low 10-year high

EV/Sales against its own 10 years 46.12%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	877	1,140	1,945	2,229
Receivables	161	159	182	239
Inventory	31	23	80	91
Other	—	—	—	—
	1,219	1,366	2,274	2,617

	2023	2024	2025	Q'26
Payables	392	304	381	382
ST’ Debt	194	258	570	370
Other	—	—	—	—
	603	581	968	771

Compound Annual Growth %

	10y	5y	3y
Sales	46.99%	35.37%	35.30%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	273	361	—	—	—
’25	1,176	179	211	165	1,731
’24	210	187	197	213	807
’23	220	214	197	307	938
’22	149	166	217	167	699
’21	118	117	139	165	539
’20	68	75	118	119	381

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(59)	129	—	—	—
’25	870	(58)	(66)	(34)	711
’24	71	(71)	(77)	(30)	(108)
’23	(29)	(14)	(15)	(100)	(158)
’22	(97)	(55)	(38)	(166)	(357)
’21	(100)	(31)	(51)	(69)	(251)
’20	(82)	(75)	27	(64)	(194)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(60)	122	—	—	—
’25	868	(62)	(322)	(37)	702
’24	6	(36)	(143)	(37)	(154)
’23	(73)	(33)	(90)	(129)	(279)
’22	(179)	(73)	(64)	(193)	(509)
’21	(120)	(39)	(99)	(93)	(337)
’20	(99)	(77)	(2)	(83)	(250)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.03)	0.92	—	—	—
’25	10.04	(0.83)	0.20	(1.67)	7.78
’24	(1.20)	(1.29)	(1.39)	(0.85)	(4.73)
’23	(1.88)	(2.66)	(1.76)	(2.06)	(8.37)
’22	(1.78)	(2.13)	(1.53)	(2.35)	(7.79)
’21	(1.83)	(1.68)	(1.89)	(2.03)	(7.43)
’20	(1.81)	(2.78)	(1.03)	(1.08)	(6.64)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.03	8.12	16.38	27.53	30.79	34.85	25.01	17.53	23.58	35.95	Analyst estimates 2026–2028 Powerpack
	High	31.89	22.00	52.95	50.96	68.81	70.82	55.58	59.84	54.16	87.50
People
People	Employees	304	373	517	761	967	1,177	1,410	995	939	991
	Revenue/emp, $m	0.27	0.52	0.51	0.40	0.39	0.46	0.50	0.94	0.86	1.75
Income, $m
Income, $m	Revenue	83	194	265	307	381	539	699	938	807	1,731
	Gross margin, %	100.00	97.65	95.21	96.05	95.03	94.00	93.61	93.02	92.89	97.28
	EBT	(142)	(78)	(128)	(240)	(403)	(518)	(587)	(696)	(363)	697
	EBT margin, %	(171.14)	(39.95)	(48.39)	(78.16)	(105.82)	(96.24)	(84.07)	(74.23)	(45.01)	40.25
	Net income	(142)	(79)	(128)	(252)	(438)	(524)	(559)	(627)	(363)	683
	Depreciation	5	19	26	31	86	71	166	454	224	22
Per share, $
Per share, $	Revenue	2.43	4.96	5.68	5.22	5.77	7.64	9.74	12.53	10.50	21.76
	Earnings	(4.17)	(2.02)	(2.75)	(4.27)	(6.64)	(7.43)	(7.79)	(8.37)	(4.73)	8.58
	Cash flow	(3.04)	(0.26)	(0.59)	(1.68)	(2.94)	(3.57)	(4.97)	(2.12)	(1.40)	8.94
	Capex	(0.05)	(2.05)	(0.33)	(0.77)	(0.85)	(1.21)	(2.13)	(1.61)	(0.60)	(0.11)
	Free cash flow	(3.09)	(2.31)	(0.93)	(2.45)	(3.79)	(4.78)	(7.10)	(3.73)	(2.00)	8.83
	Book value	3.51	3.99	7.53	10.10	7.30	0.02	(4.84)	(10.94)	(14.29)	(2.58)
	Shares, m	34	39	47	59	66	70	72	75	77	80
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.64
	P/S	4.62	3.52	6.04	9.21	10.58	5.21	3.92	2.24	4.30	3.49
	P/B	3.20	4.37	4.56	4.76	8.36	1,951.79	0.00	0.00	0.00	0.00
	EV/Sales	3.01	3.28	5.76	8.00	10.34	5.98	5.26	3.56	5.84	3.87
	EV/FCF	(2.36)	(48.47)	(43.87)	(16.52)	(14.43)	(8.86)	(7.22)	(10.25)	(20.35)	15.10
Cash, $m
Cash, $m	Operating cash flow	(104)	(10)	(28)	(99)	(194)	(251)	(357)	(158)	(108)	711
	Capex	(2)	(80)	(16)	(45)	(56)	(85)	(152)	(121)	(46)	(9)
	Free cash flow	(105)	(90)	(43)	(144)	(250)	(337)	(509)	(279)	(154)	702
Balance, $m
Balance, $m	Working capital	212	167	154	543	954	445	288	616	785	1,306
	Total debt	98	145	153	314	1,012	1,185	1,348	2,115	2,383	2,598
	Net debt	(133)	(46)	(75)	(373)	(92)	412	938	1,239	1,243	653
	Shareholders’ equity	120	156	351	594	482	1	(347)	(819)	(1,098)	(205)
Returns, %
Returns, %	ROA	(44.79)	(23.90)	(16.95)	(18.34)	(22.87)	(25.27)	(30.68)	(34.80)	(20.18)	29.66
	ROIC	0.00	(36.48)	(26.18)	(68.01)	(69.14)	(56.59)	(47.36)	(65.37)	(130.42)	121.13
	ROE	(82.24)	(57.24)	(50.51)	(53.24)	(81.42)	(216.75)	323.46	107.51	37.91	(104.75)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CGON CG Oncology, Inc.	$5.5B	— (loss-making)	— (loss-making)	+2,125.00% (above 0%: growing)	n/m	−67.60% (below 0%: shrinking)	(239.24%)	(7,467.68%)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)	Compare
ERAS Erasca, Inc.	$5.2B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%	Compare
PTCT PTC Therapeutics, Inc.	$5.1B	— (loss-making)	110×	+101.55% (above 0%: growing)	n/m	+295.69% (above 0%: growing)	94.47%	41.32%
CRSP CRISPR Therapeutics AG	$5.0B	— (loss-making)	— (loss-making)	+1,041.37% (above 0%: growing)	n/m	+26.19% (above 0%: growing)	100.00%	(1,151.84%)	Compare
TVTX Travere Therapeutics, Inc.	$5.0B	— (loss-making)	196×	+48.17% (above 0%: growing)	n/m	+604.22% (above 0%: growing)	98.72%	2.33%	Compare
SRRK Scholar Rock Holding Corporation	$5.0B	— (loss-making)	— (loss-making)	+605.03% (above 0%: growing)	n/m	+8.88% (above 0%: growing)	0.00%	0.00%	Compare
ORKA Oruka Therapeutics, Inc.	$4.9B	— (loss-making)	—	—	n/m	−43.00% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$5.1B	—	—	+326.60%	—	−23.34%	0.00%	0.00%

All 614 Biotechnology stocks →

PTC Therapeutics, Inc. (PTCT) key facts

Strength: PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
PTC Therapeutics, Inc. (PTCT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PTCT traded at $59.24, a market capitalization of $5.1 billion.
Return on equity was −104.8% and debt-to-equity -17.61.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 1.86 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.